Table 1.
Characteristics of all consented participants (n=28).a
| Characteristics | All participants who consented for the study (n=28), n (%) | Participants who consented and completed the welcome phase (n=15), n (%) | Participants who consented but did not complete the welcome phase (n=13), n (%) | P value | |||||
| Age range (years) | .42 | ||||||||
|
|
18-29 | 5 (18) | 4 (27) | 1 (8) |
|
||||
|
|
30-45 | 9 (32) | 5 (33) | 4 (31) |
|
||||
|
|
46-64 | 14 (50) | 6 (40) | 8 (62) |
|
||||
| Gender | .33 | ||||||||
|
|
Woman | 5 (18) | 4 (27) | 1 (8) |
|
||||
|
|
Man | 23 (82) | 11 (73) | 12 (92) |
|
||||
| Race | .37 | ||||||||
|
|
American Indian or Alaska Native | 1 (4) | 0 (0) | 1 (8) |
|
||||
|
|
Black or African American | 3 (11) | 2 (13) | 1 (8) |
|
||||
|
|
Hispanic, Latino, Latina, or Spanish origin | 4 (14) | 1 (7) | 3 (23) |
|
||||
|
|
Middle Eastern or North African | 1 (4) | 1 (7) | 0 (0) |
|
||||
|
|
White or Caucasian | 16 (57) | 8 (53) | 8 (62) |
|
||||
|
|
More than one race | 3 (11) | 3 (20) | 0 (0) |
|
||||
| Marital status | .29 | ||||||||
|
|
Single, divorced, or widowed | 22 (79) | 10 (67) | 12 (92) |
|
||||
|
|
Married or committed relationship | 3 (11) | 2 (13) | 1 (8) |
|
||||
|
|
Other or unknown marital status | 3 (11) | 3 (20) | 0 (0) |
|
||||
| Sexual orientation minority group | 11 (39) | 8 (53) | 3 (23) | .14 | |||||
| Past–30-day methamphetamine use | .02 | ||||||||
|
|
5-9 days | 4 (14) | 1 (7) | 3 (23) |
|
||||
|
|
10-14 days | 4 (14) | 1 (7) | 3 (23) |
|
||||
|
|
15-20 days | 7 (25) | 7 (47) | 0 (0) |
|
||||
|
|
21-30 days | 13 (46) | 6 (40) | 7 (54) |
|
||||
| Methamphetamine goal | >.99 | ||||||||
|
|
Abstinence | 21 (75) | 11 (73) | 10 (77) |
|
||||
|
|
Nonabstinent reduction | 7 (25) | 4 (27) | 3 (23) |
|
||||
| Prescribed medications for opioid use disorder | .46 | ||||||||
|
|
Buprenorphine | 14 (50) | 5 (33) | 9 (69) |
|
||||
|
|
Injectable naltrexone | 2 (7) | 2 (13) | 0 (0) |
|
||||
|
|
Methadone | 1 (4) | 1 (7) | 0 (0) |
|
||||
|
|
None | 11 (39) | 7 (47) | 4 (31) |
|
||||
| Other EHRb-based substance use and mental health disorder measures | |||||||||
|
|
Prescribed amphetamine medication | 1 (4) | 1 (7) | 0 (0) | >.99 | ||||
|
|
Co-occurring nonamphetamine SUDc (per EHR) | 22 (79) | 12 (80) | 10 (77) | >.99 | ||||
|
|
Co-occurring mental health disorder (per EHR) | 25 (89) | 15 (100) | 10 (77) | .09 | ||||
aP values were obtained using Fisher exact tests and reflect differences between participants who completed the welcome phase and those who did not complete the welcome phase.
bEHR: electronic health record.
cSUD: substance use disorder.